Alkylating agents
HIPEC for Recurrent Ovarian Cancer
Recruiting1 awardPhase 1
Loma Linda, California
This trial is comparing the effectiveness of two different treatments for ovarian, primary peritoneal, or fallopian tube cancer that has come back. One treatment is surgery to remove as much of the cancer as possible, followed by a single dose of chemotherapy given through the abdomen directly to the area where the cancer was. The other treatment is 6 cycles of standard chemotherapy given intravenously.
PARP Inhibitor
Oregovomab + Niraparib for Ovarian Cancer
Recruiting1 awardPhase 2
Durham, North Carolina
This trial tests a new treatment combining two drugs, oregovomab and niraparib, for patients with ovarian cancer that has come back but still responds to certain chemotherapy. The treatment aims to help the immune system better recognize and destroy cancer cells while also preventing the cancer cells from fixing themselves. About 10 patients will be treated and monitored for safety and effectiveness. Niraparib is approved for use in patients with newly-diagnosed or recurrent ovarian cancer.
Monoclonal Antibodies
Pembrolizumab + Bevacizumab for Ovarian Cancer
Recruiting1 awardPhase 2
Buffalo, New York
This trial is testing a new immunotherapy treatment for ovarian cancer. The treatment includes two monoclonal antibodies and a drug that stimulates the immune system. The goal is to shrink tumors and improve quality of life for patients with ovarian cancer.
mTORC1/2 Inhibitor
mTOR/AKT Inhibitors for Endometrial and Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing the side effects and best dose of two different drug combinations in treating patients with recurrent endometrial, triple negative breast cancer, ovarian, primary peritoneal, or fallopian tube cancer.
Popular Filters
Trials for Ovarian Cancer Patients
CDK4/6 Inhibitor
Ribociclib + Belinostat for Breast Cancer
Recruiting1 awardPhase 1
Salt Lake City, Utah
This trial is designed to assess the maximum tolerated dose of two drugs, ribociclib and belinostat, in combination. The trial will start with a dose escalation, followed by an expansion cohort at the identified dose. Dose escalation will be open to patients with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients with triple-negative breast cancer.
Platinum-based Chemotherapy
Chemo-Immunotherapy for Recurrent Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial will test a new combination of drugs to treat ovarian cancer. The drugs will be given through IV and intraperitoneal (IP) infusion. The trial will evaluate the effectiveness and safety of the new combination.
Monoclonal Antibodies
REGN4018 + Cemiplimab for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is studying REGN4018, given alone or together with cemiplimab, to see how well it works in treating patients with solid tumors that have spread (metastatic) or cannot be removed by surgery (unresectable).
Trials for SOC Patients
CDK4/6 Inhibitor
Ribociclib + Belinostat for Breast Cancer
Recruiting1 awardPhase 1
Salt Lake City, Utah
This trial is designed to assess the maximum tolerated dose of two drugs, ribociclib and belinostat, in combination. The trial will start with a dose escalation, followed by an expansion cohort at the identified dose. Dose escalation will be open to patients with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients with triple-negative breast cancer.
Platinum-based Chemotherapy
Chemo-Immunotherapy for Recurrent Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial will test a new combination of drugs to treat ovarian cancer. The drugs will be given through IV and intraperitoneal (IP) infusion. The trial will evaluate the effectiveness and safety of the new combination.
Monoclonal Antibodies
REGN4018 + Cemiplimab for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is studying REGN4018, given alone or together with cemiplimab, to see how well it works in treating patients with solid tumors that have spread (metastatic) or cannot be removed by surgery (unresectable).
Trials for Metastatic Patients
CDK4/6 Inhibitor
Ribociclib + Belinostat for Breast Cancer
Recruiting1 awardPhase 1
Salt Lake City, Utah
This trial is designed to assess the maximum tolerated dose of two drugs, ribociclib and belinostat, in combination. The trial will start with a dose escalation, followed by an expansion cohort at the identified dose. Dose escalation will be open to patients with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients with triple-negative breast cancer.
Monoclonal Antibodies
REGN4018 + Cemiplimab for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is studying REGN4018, given alone or together with cemiplimab, to see how well it works in treating patients with solid tumors that have spread (metastatic) or cannot be removed by surgery (unresectable).
Alkylating agents
Chemoimmunotherapy + Vaccines for Recurrent Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial will test a treatment plan for advanced ovarian cancer patients. They will first receive a combination of drugs directly into the abdominal cavity and through the vein. Then, they will receive another treatment containing a
Alkylating agents
CPI-0209 + Carboplatin for Ovarian Cancer
Recruiting1 awardPhase 1
Pittsburgh, Pennsylvania
This trial is testing a new drug, CPI-0209, combined with chemotherapy in patients with recurrent ovarian cancer. The goal is to see if CPI-0209 can make chemotherapy work better and prevent the cancer from returning by blocking resistance and spread.
Trials for BRCA Positive Patients
PARP Inhibitor and ATR Inhibitor
ATR Inhibitor + PARP Inhibitor for Ovarian Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial will test a new combination of drugs to treat ovarian cancer. The drugs will be given to women who have had the disease come back after treatment. The study will look at if the combination is safe and works well.
Tyrosine Kinase Inhibitor
Cediranib + Olaparib for Ovarian Cancer
Recruiting1 awardPhase 2
Phoenix, Arizona
This study is evaluating whether a drug called olaparib and a drug called cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent).
Alkylating agents
CPI-0209 + Carboplatin for Ovarian Cancer
Recruiting1 awardPhase 1
Pittsburgh, Pennsylvania
This trial is testing a new drug, CPI-0209, combined with chemotherapy in patients with recurrent ovarian cancer. The goal is to see if CPI-0209 can make chemotherapy work better and prevent the cancer from returning by blocking resistance and spread.
CAR T-cell Therapy
FSHR-Targeted T Cell Therapy for Ovarian Cancer
Recruiting2 awardsPhase 1
Tampa, Florida
This trial is testing a new treatment that uses a patient's own modified immune cells to target and kill cancer cells. It focuses on patients whose ovarian, fallopian tube, or primary peritoneal cancer has come back or hasn't responded to other treatments.
Phase 3 Trials
Taxane
Pembrolizumab + Paclitaxel +/- Bevacizumab for Ovarian Cancer
Recruiting1 awardPhase 3
Sarasota, Florida
This trial is testing a new cancer treatment combining two drugs, pembrolizumab and paclitaxel, with or without bevacizumab. The goal is to see if this new combination can prolong the amount of time until the cancer progresses, compared to the current standard treatment.
Monoclonal Antibodies
Sacituzumab Tirumotecan for Ovarian Cancer
Recruiting2 awardsPhase 3
Omaha, Nebraska
This trial aims to see if a new combination of drugs is safe and well-tolerated for people with cancer. It also wants to find out if this new treatment helps people live longer without their cancer
Tyrosine Kinase Inhibitor
Olaparib vs. Cediranib + Olaparib for Recurrent Ovarian Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is comparing two different treatments for ovarian, fallopian tube, or primary peritoneal cancer that has come back. One treatment is a standard chemotherapy treatment, and the other is a new treatment that uses two drugs, olaparib and cediranib maleate. The trial will see if the new treatment is more effective than the standard chemotherapy treatment.
Alkylating agents
Chemotherapy +/− Bevacizumab for Ovarian Cancer
Recruiting2 awardsPhase 3
Anchorage, Alaska
This trial is studying carboplatin, paclitaxel, and gemcitabine hydrochloride given together with or without bevacizumab after surgery to treat patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer.
Trials With No Placebo
CDK4/6 Inhibitor
Ribociclib + Belinostat for Breast Cancer
Recruiting1 awardPhase 1
Salt Lake City, Utah
This trial is designed to assess the maximum tolerated dose of two drugs, ribociclib and belinostat, in combination. The trial will start with a dose escalation, followed by an expansion cohort at the identified dose. Dose escalation will be open to patients with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients with triple-negative breast cancer.
Platinum-based Chemotherapy
Chemo-Immunotherapy for Recurrent Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial will test a new combination of drugs to treat ovarian cancer. The drugs will be given through IV and intraperitoneal (IP) infusion. The trial will evaluate the effectiveness and safety of the new combination.
Monoclonal Antibodies
REGN4018 + Cemiplimab for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is studying REGN4018, given alone or together with cemiplimab, to see how well it works in treating patients with solid tumors that have spread (metastatic) or cannot be removed by surgery (unresectable).
PARP Inhibitor and ATR Inhibitor
ATR Inhibitor + PARP Inhibitor for Ovarian Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial will test a new combination of drugs to treat ovarian cancer. The drugs will be given to women who have had the disease come back after treatment. The study will look at if the combination is safe and works well.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.